Health

Concord Medical Announces the Successful Holding of the Second Annual Academic Meeting with the world well-known MD Anderson

BEIJING, Nov. 16, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensi...

2022-11-16 20:55 3525

Xiantao Zhengxin Group Introduces a Fully Automated Mask Production Line to Expand Production Capacity, Reduce Pollution and Contribute to Sustainable Development

Xiantao Zhengxin Group triples production capacity with its fully automated mask production machines XIANTAO, China, Nov. 15, 2022 /PRNewswire/ -- Zhengxin Group (Zhengxin) is proud to introduce its new fully automatic mask production line to expand mask production capacity and start production ...

2022-11-16 11:56 2002

Simcere and Idorsia enter into a licensing agreement for daridorexant in China

NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the discovery, development and commercialization of small molecules to transform the hori...

2022-11-16 08:32 3250

Island to present at World Antiviral Congress 2022

MELBOURNE, Australia, Nov. 15, 2022 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to advise that CEO and Managing Director, DrDavid Foster will present at the World Antiviral Congress 2022 inSan Diego, USA which ...

2022-11-15 21:00 2166

Reistone Biopharma's oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for Atopic Dermatitis

SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- Reistone Biopharma (Reistone), a leading biotech company focused on development of innovative medicines for immune and inflammation diseases, todayannounced positive results from a Phase III study – QUARTZ3 (NCT04875169) evaluating the efficacy and safet...

2022-11-15 21:00 2546

Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue

* Nabota exports grew significantly, achieving a 93.3% growth YOY, and overall revenue topsKRW 40.4 billion * Fexuclue, a new drug released last July, shows steep growth in market share in Korea * Nabota enters the European market and Fexuclue enters wide use as in prescriptions for gastrit...

2022-11-15 20:00 1499

HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update

* Financial results for Q3 2022 ended with revenue of KRW 29.6 billion with continued growth in the pharmaceutical division driven by product portfolio expansion and strong sales in major products * R&D expenses for the quarter increased by 63%, reflecting the preparation of a Phase 3 study i...

2022-11-15 20:00 1385

EDAN Took Its Solutions up a Notch at MEDICA 2022

DUSSELDORF, Germany, Nov. 15, 2022 /PRNewswire/ -- Edan Instruments Inc. (300206.SZ) demonstrated its range of latest innovations at MEDICA, the premiere global medical trade show held atDusseldorf, Germany, from Nov. 14 to 17, 2022. Five new products are presented to bring a huge surprise to mor...

2022-11-15 18:26 1577

Nona Biosciences Announces Attendance at PEGS Europe 2022

CAMBRIDGE, Mass., Nov. 15, 2022 /PRNewswire/ -- Nona Biosciences (a wholly-owned subsidiary of HBM Holdings, HKEX: 02142) announced that the Company is attending the 14th Protein and Antibody Engineering Summit (PEGS) in Barcelona, Spain, November 14-16, 2022. The booth is located at #54. Frank ...

2022-11-15 15:57 2146

WuXi Vaccines Establishes New Vaccines CDMO Facility in China

SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- WuXi Vaccines, a leading global Contract Development and Manufacturing Organization (CDMO), announced that it has entered into an agreement with Harbour BioMed under which Harbour BioMed's manufacturing facility in Suzhou will be transferred to WuXi Va...

2022-11-15 12:45 1765

HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned subsidiary, Nona Biosciences, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND. T...

2022-11-15 12:19 1920

Biotheus has entered into a license and collaboration agreement with Hansoh Pharma for its EGFR/MET bispecific antibody in the Greater China territory

ZHUHAI, China, Nov. 14, 2022 /PRNewswire/ -- Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, announced today that they have entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheu...

2022-11-15 11:16 2127

VentureBlick Launches Global Search for Healthcare Startups 'Most Endorsed by the Medical Community'

SINGAPORE, Nov. 14, 2022 /PRNewswire/ -- VentureBlick, a fundraising platform matching healthcare startups with medical investors, has launched its worldwide search to identify promising healthcare startups for the medical community to evaluate, advise, and fund. Only startups that receive endors...

2022-11-15 09:00 2730

AIRS Medical showcases award-winning MRI enhancement AI solution at RSNA 2022

SEOUL, South Korea, Nov. 14, 2022 /PRNewswire/ -- AIRS Medical, Inc., a leading medical AI solution provider, announced its participation in the 108th Scientific Assembly and Annual Meeting of the Radiological Society ofNorth America (RSNA 2022), the world's leading annual imaging forum at McC...

2022-11-14 23:00 2524

Shiang Ding Targets US Market With Healthy Herbal Beverage Alternatives

TAIPEI, Nov. 14, 2022 /PRNewswire/ -- Shiang Ding Food Co. (Shiang Ding), one of Taiwan's premier food wholesalers, announced new plans to expand access to healthy, herbal tea and coffee alternatives in the US market via its Tan...

2022-11-14 23:00 2681

The World's First ETa-specific Monoclonal Antibody: Gmax Biopharm's GMA131 Approved by the US FDA for Clinical Study on (DKD) Diabetic Kidney Disease

HANGZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Gmax Biopharm LLC. announced today that its application of investigation of New Drug (IND) for GMA131 injection, the first global ETa-specific monoclonal antibody, was approved by the US FDA onNov 11, 2022 for clinical study on diabetic kidney diseas...

2022-11-14 22:55 2589

Meihua International Medical Technologies Co., Limited Reports Unaudited 2022 First Half Financial Results

YANGZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Limited ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today reported its unaudited...

2022-11-14 21:00 2154

Nuance Pharma Announces Clearance of IND Application for Respiratory Syncytial Virus (RSV) Vaccine in China

SHANGHAI, Nov. 13, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial virus (RSV) in a...

2022-11-14 09:54 2046

SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969

State-run financing to provide two-year support of Phase 1 research for oncology candidate, SKL27969, for the potential treatment of advanced solid tumors SK Biopharmaceuticals to present preclinical data on oncology candidate, SKL27969, at Society for Neuro-Oncology Conference PANGYO, South Ko...

2022-11-14 08:00 2510

Akeso's Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China

* AK112 has now been granted three Breakthrough Therapy Designations for NSCLC * The only drug candidate granted Breakthrough Therapy Designation for I-O Resistance NSCLC inChina HONG KONG, Nov. 13 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") announced that the Center for Drug Evaluati...

2022-11-14 08:00 2196
1 ... 117118119120121122123 ... 273